Indication

GLP-1 medications for Cardiovascular risk reduction

GLP-1 medications for Cardiovascular risk reduction, with sourced prices, shortage reports and study results.

Last updated

Last checked · Nov 16, 2026 UTC
4approved

Approved for this use

Alphabetical by active ingredient. Approved uses depend on the specific brand and formulation.

Dulaglutide

Trulicity

FDA-approved for

  • Type 2 diabetes
  • Heart risk

Subcutaneous injection · Once weekly

FDA shortage report (accessdata.fda.gov/scripts/drugshortages)

Published entry quote

from $389/28 days (lilly.com/lillydirect/trulicity)

Trulicity single-dose pens · LillyDirect (Eli Lilly)

Checked on lilly.com

Price conditions

self-pay, four weekly pens; published starting rate at each dose

The self-pay program requires a prescription for an approved use, age 18+, and US or Puerto Rico residence. Purchases cannot be submitted to insurance or counted toward deductibles or out-of-pocket limits. LillyDirect defines a month's supply as four single-dose pens, one a week, so a fill covers 28 days.

28-day supply

Checked . Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety

Liraglutide

Victoza, Saxenda

FDA-approved for

  • Weight loss
  • Type 2 diabetes
  • Heart risk

Subcutaneous injection · Once daily

FDA shortage reportIn shortage (accessdata.fda.gov/scripts/drugshortages)

Published entry quote

from $349/mo (healifynow.com/saxenda)

Saxenda via HealifyNow · HealifyNow

Checked on healifynow.com

Price conditions

its Saxenda page says "From $349/month" for Saxenda (liraglutide 3 mg, weight management), and "Your first consultation is free. No insurance needed, and you only pay if you start treatment." On the same page, "Can I cancel my Saxenda plan at any time?" is answered "Yes. There are no contracts, and you can cancel from your patient portal."

A starting price: the page does not say what the figure includes or how it changes with the dose; the page prices it per month with no contracts. Its pages also list "Liraglutide From $149/mo" without saying which kind of liraglutide it is. FDA-approved product.

Checked . Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety

Semaglutide

Ozempic, Wegovy, Wegovy HD, Rybelsus

FDA-approved for

  • Weight loss
  • Type 2 diabetes
  • Heart risk
  • Kidney
  • Liver

Subcutaneous injection (Ozempic, Wegovy); oral tablet (Rybelsus, oral Ozempic, Wegovy pill) · Once weekly (injectable); once daily (oral)

FDA shortage report (accessdata.fda.gov/scripts/drugshortages)

Published entry quote

$149/30 days (pharmacy.amazon.com/Novo-Nordisk-Inc-WEGOVY-1-5-MG-TABLET-Bottle-30-Tablet/dp/B0GD6568YL)

Wegovy pill via Amazon Pharmacy · Amazon Pharmacy

Checked on pharmacy.amazon.com

Price conditions

without insurance, 1.5 mg; includes the manufacturer coupon if eligible (list price $1,348.80); prescription required

Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

30-day supply

Checked . Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety

Tirzepatide

Mounjaro, Zepbound

FDA-approved for

  • Weight loss
  • Type 2 diabetes
  • Heart risk
  • Sleep apnea

Subcutaneous injection · Once weekly

FDA shortage report (accessdata.fda.gov/scripts/drugshortages)

Published entry quote

$299/28 days (pharmacy.amazon.com/ZEPBOUND-KWIKPEN-2-5-MG-DOSE-PEN-INJ/dp/B0GP27N9T3)

Zepbound KwikPen via Amazon Pharmacy · Amazon Pharmacy

Checked on pharmacy.amazon.com

Price conditions

without insurance, 2.5 mg; includes the manufacturer coupon if eligible (list price $498.98); prescription required

The 7.5 mg KwikPen is also $449. Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

28-day supply

Checked . Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety
Word for word

What each FDA label says about cardiovascular risk reduction

From the indications section of each manufacturer's current label. A brand's wording decides who it is approved for.

  • Mounjaro: “to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.”FDA label, revised Aug 27, 2026 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
  • Ozempic: “to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.”FDA label, revised Jun 1, 2026 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
  • Rybelsus and Ozempic tablets: “to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.”FDA label, revised Jan 30, 2026 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
  • Trulicity: “To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.”FDA label, revised Jun 16, 2026 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
  • Victoza: “to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.”FDA label, revised Oct 14, 2025 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
  • Wegovy: “to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. to reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.”FDA label, revised Jun 18, 2026 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)

Do GLP-1s lower the risk of heart attack and stroke? What the trials found

From FDA and CMS records

Timing, generics and coverage

Read from each FDA label, FDA's Orange Book and CMS's Part D files, and updated when they change.

BrandSoonest top doseHalf-lifeGeneric approved?Patent on the medicine toOn Medicare Part D, 2025
Ozempic2 mg from week 13about 1 weekNot yet: tentative onlyDec 5, 20312,044,798
Wegovy7.2 mg from week 21about 1 weekNoDec 5, 2031108,843
Rybelsus14 mg from day 61about one weekNoMay 2, 2034280,455
Mounjaro15 mg from week 21about 5 daysNoJun 14, 20391,592,517
Zepbound15 mg from week 21about 5-6 daysNoMay 13, 2036160,298
Victoza1.8 mg from week 3about 13 hoursYes, 8None listed6,810
Saxenda3 mg from week 5about 13 hoursYes, 3None listedNone listed
Trulicity4.5 mg from week 13about 5 daysNo, it is a biologicNot in the Orange Book582,333

How long each takes · Generics and patents · Who covers what

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.